Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
To get a sense of who is truly in control of OptimizeRx Corporation ( NASDAQ:OPRX ), it is important to understand the...
OptimizeRx Corp. (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
OPRX CEO Will Febbo provides business update and key industry trendsOPRX conference presentation to begin at 8:15 AM PT on January 12, 2023 ROCHESTER, Mich., Jan. 04, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy announced OptimizeRx’s CEO Will Febbo is invited to speak at the upcoming J.P. Morgan Healthcare Conference. The OPRX conference presentation is scheduled to b
ROCHESTER, Mich., Nov. 28, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced that management will participate in the following upcoming investor conferences: Piper Sandler 34th Annual Healthcare Conference, New York City, November 29th – December 1st 2022 J.P. Morgan Healthcare Conference, San Francisco, January 9th – January 12th 2023 LifeSci Partners Corp
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, its Investor Class fund ARTSX returned 3.23%, Advisor Class fund APDSX posted a return of 3.27%, and Institutional Class fund APHSX returned 3.27%, compared to a […]
OptimizeRx ( NASDAQ:OPRX ) Third Quarter 2022 Results Key Financial Results Revenue: US$15.1m (down 6.4% from 3Q 2021...
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 75% and 0.47%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Q3 Revenue of $15.1 million, down 6% year-over-year and up 8% quarter-over-quarterGross profit increased 4% year-over-year to $9.4 million as gross margins increased from 56% to 62%Generated $7.9 million in cash flow from operations during the first nine months of 2022Repurchased 1.1 million shares - year to date - at an average price of $16.70 per share ROCHESTER, Mich., Nov. 08, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care techno
Some OptimizeRx Corporation ( NASDAQ:OPRX ) shareholders are probably rather concerned to see the share price fall 40...